<DOC>
	<DOC>NCT02898506</DOC>
	<brief_summary>The objective of the trial is to study whether daily treatment with liraglutide improves endogenous insulin secretion, postpones progression to overt Type 1 diabetes, and is tolerable and safe in subjects aged 10-30 years, who are positive for multiple islet autoantibodies and have dysglycemia.</brief_summary>
	<brief_title>Incretin-based Therapy in Late Preclinical Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1030 years of age positive for at least 2 islet autoantibodies glucose intolerance or dysglycemia: impaired glucose tolerance (IGT, 2hour pgluc 7.811.0mmol/l), or impaired fasting glucose (IFG, fpgluc 6.16.9mmol/l), and/or 10% rise in HbA1c since the last measurement (2 12 mo ago), and/or pgluc at least 11.1mmol/l at 30, 60 or 90 min during OGTT not pregnant allergic to liraglutide or other ingredients of Victoza type 1 diabetes diabetic ketoacidosis previous treatment in the last three months with any antidiabetic medication impaired liver or kidney function or on dialysis severe heart failure severe stomach or gut problem resulting in gastroparesis, or inflammatory bowel disease past or current history of pancreatitis serum calcitonin value above normal (&gt;50 ng/l or at least 3.4pmol/l) presence of any chronic metabolic, hematologic or malignant disease obesity BMI at least 30 pregnant females and females of childbearing potential who are not using adequate contraceptive methods. breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetes Type 1</keyword>
	<keyword>Diabetes, Insulin-Dependent</keyword>
	<keyword>Liraglutide</keyword>
	<keyword>Preclinical Type 1 Diabetes</keyword>
	<keyword>GLP-1 Analogue</keyword>
	<keyword>Dysglycemia</keyword>
	<keyword>Prevention</keyword>
</DOC>